EUCTR2008-007969-23-GR进行中（未招募）1 期
A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,015
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Understand and voluntarily sign an Informed Consent Form (ICF)
- •2. Males = 18 years of age at the time of consent
- •3. Able to adhere to the study visit schedule and requirements of the protocol
- •4. ECOG performance status of = 2
- •5. Life expectancy of = 12 weeks
- •6. Willingness to participate in HRQoL and pain assessments and have ability to complete PRO and pain assessments without assistance or with minimal assistance from trained site personnel and/or caregiver
- •7. Effective castration (defined as serum testosterone levels < 50 ng/dL):
- •-Primary testicular androgen suppression (e.g., LHRH agonists or antagonists) should be continued during study treatment for subjects who have not had a bilateral orchiectomy.
- •8. Histologically confirmed adenocarcinoma of the prostate and:
- •- Prostate cancer that is unresponsive or refractory to hormonal therapy AND
- •- Metastatic disease confirmed by bone scan, CT scan, MRI, or X-Ray
- •9. Have documented disease progression while receiving or following hormonal therapy for treatment of advanced prostate cancer despite castrate levels of serum testosterone due to orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist as determined by at least one of the following criteria:
- •-Serum PSA level = 2ng/mL that has increased from a reference value (the last value
- •immediately prior to the first rise) on at least two consecutive PSA measurements
- •obtained at least 1 week apart prior to randomization
- •- Progression of measurable disease
- •- Measurable disease is defined as at least one measurable lesion = 10 mm in the longest diameter by CT or MRI (or 20 mm by chest X-ray) and/or lymph nodes = 15 mm
- •- Progression of measurable disease is defined as an increase of = 20% in the sum of
- •the diameters of target lesions from the time of maximal regression with an absolute
- •increase of = 5mm, OR the appearance of = 1 new lesion
- •-Unequivocal progression of non-measurable disease
- •-Non-measurable disease is defined as all lesions < 10mm in the longest diameter
- •or pathological lymph nodes =10 mm to < 15 mm short axis
- •-Unequivocal progression of existing lesions is defined as an increase in
- •overall disease burden based on the change in non-measurable disease that is
- •comparable in magnitude to the increase that would be required to declare
- •disease progression for measurable disease
- •-2 or more new bone lesions as detected by bone scan
- •10. All subjects:
- •- Must be counseled about pregnancy precautions and risks of fetal exposure. See Appendix 21.7.2 Lenalidomide Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods, and Appendix 21.7.3 Lenalidomide Education and Counseling Guidance Document
- •-Must agree to use a condom (specified in the appropriate country specific appendix) during sexual contact with a female of childbearing potential (FCBP)d, even if they have had a vasectomy, while participating in this study, during dose interruptions, and for a period of 28 days following the last dose of study drug
- •- Must agree to refrain from donating semen or sperm while participating in this study and for a period of 28 days following the last dose of study drug.
- •- Must agree to refrain from donating blood or plasma while participating in this study and for a period of 28 days following the last dose of study drug
- •-Must agree not to share study drug with anyone during participation in the study
排除标准
- •1. A history of clinically significant (as determined by the investigator) medical, surgical, or psychiatric disease that would place the subject at an unacceptable risk for study entry
- •2. Prior therapy with thalidomide, lenalidomide (CC-5013) or pomalidomide (CC-4047),
- •3. Prior chemotherapy for prostate cancer
- •-Treatment with estramustine will be allowed if last treatment is more than 28 days
- •prior to randomization, and subject has recovered from side effects
- •-Adjuvant and/or neoadjuvant treatment will be allowed if completed > 3 years prior to randomization and provided the treatment was a non-taxane based regimen
- •4. Use of any other experimental drug or therapy within 28 days prior to randomization.
- •5. Prior radiation therapy to = 30% of bone marrow as determined by review of Appendix 21.4 and/or consultation with radiation specialist
- •6. Any other radiation therapy within 28 days prior to randomization
- •-Subjects receiving prior radiation must have recovered from acute toxicity or any side effects due to radiation treatments prior to randomisation
- •7. Prior use of Strontium-89 at any time or Samarium-153 within 56 days prior to
- •randomization.
- •8. Surgery within 28 days prior to randomization (minimally invasive procedures for the purpose of diagnosis or staging of the disease are permitted).
- •9. Concurrent antiandrogen therapy as follows:
- •- Treatment with antiandrogens, (e.g., flutamide), aminoglutethimide, megestrol or diethylstilbestrol (DES) must be discontinued at least 4 weeks prior to randomization
- •-Treatment with bicalutimide and nilutamide must be discontinued at least 6 weeks prior to randomization
- •- Subjects exhibiting clinical symptoms and/or radiologic evidence of rapidly progressive disease will be allowed to initiate treatment if in the clinical judgement of the investigator a 4- or 6-week delay for anti-androgen washout would compromise the health and safety of the study subject
- •-Subjects without prior orchiectomy should continue treatment with LHRH agonists or antagonists
- •- Bisphosphonates may be used if treatment was initiated at least 28 days prior to randomisation
- •-Concurrent therapy with steroids or hormones for adrenal insufficiency or
- •nondisease-related conditions (e.g., insulin for diabetes) are allowed
- •10. Any of the following laboratory values:
- •-Hemoglobin < 9 g/dL (blood products and growth factors are permitted.)
- •-Absolute neutrophil count (ANC) < 1.5 x 109 cells/L
- •- Platelet count < 100 x 109 cells/L
- •-Creatinine clearance < 50mL/min by Cockcroft-Gault formula
- •- Total bilirubin > 1.0 x the ULN
- •-Serum aspartate amino transaminase (AST)/SGOT > 1.5 x ULN concomitant with
- •alkaline phosphatase > 2.5 x ULN
- •11. Must not have had significant active cardiac disease within the previous 6 months
- •- History of uncontrolled hypertension (i.e., BP > 160/90 mm Hg) despite anti-hypertensive therapy
- •-New York Heart Association class II-IV congestive heart failure
- •- Unstable angina
- •-Angina requiring surgical or medical intervention
- •-Myocardial infarction
- •12. Clinically significant peripheral arterial occlusive disease (i.e., claudication on less than 1 block)
- •13. Thrombotic or thromboembolic events within the past 6 months, including any of the following:
- •-Deep Vein Thrombosis or Pulmonary Embolism within the preceding 6 months
- •-Transient ischemic attack
- •-Cerebrovascular accident
- •-Any other arterial thrombotic event
- •14. Current or history of periphe
研究者
相似试验
进行中（未招募）
1 期
The evaluation of lenalidomide, with or without Docetaxel plus Prednisone, in the treatment of prostate cancer, when the cancer does not respond to hormonal treatmentChemo-naïve metastatic prostate cancer subjects with documented rising Prostate Specific Antigen (PSA) or documented Progressive Disease (PD) following hormonal therapyMedDRA version: 18.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-007969-23-DECelgene Corporation1,059
进行中（未招募）
1 期
The evaluation of lenalidomide, with or without Docetaxel plusPrednisone, in the treatment of prostate cancer, when the cancer does not respond to hormonal treatmentChemo-naïve metastatic prostate cancer subjects with documented rising Prostate Specific Antigen (PSA) or documented Progressive Disease (PD) following hormonal therapyMedDRA version: 15.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-007969-23-SECelgene Corporation1,059
进行中（未招募）
1 期
The evaluation of lenalidomide, with or without Docetaxel plusPrednisone, in the treatment of prostate cancer, when the cancer does not respond to hormonal treatmentChemo-naïve metastatic prostate cancer subjects with documented rising Prostate Specific Antigen (PSA) or documented Progressive Disease (PD) following hormonal therapyMedDRA version: 19.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-007969-23-DKCelgene Corporation1,059
进行中（未招募）
1 期
The evaluation of lenalidomide, with or without Docetaxel plus Prednisone, in the treatment of prostate cancer, when the cancer does not respond to hormonal treatmentEUCTR2008-007969-23-GBCelgene Corporation1,059
已完成
不适用
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis-K21K21PER-028-06TAP PHARMACEUTICAL PRODUCTS INC.,